NU 641 Week 6. Case Study

Diagnosis: Acute Exacerbation of Chronic Bronchitis—Please provide your rationales for each answer with supporting data

1. Which of the following would suggest the need for antibiotic therapy in A.M.?

History of previous COPD exacerbations, cough, and fever: By analysing this answer, it suggests that the patient has a history of respiratory infections and worsening symptoms which is in line with the Anthony Miller case study. The presence of fever suggests that the patient may have an underlying bacterial infection, therefore the need for antibiotic therapy in A.M. Antibiotic therapy may be indicated for patients with acute exacerbation of chronic bronchitis if they have signs of infection, such as increased purulence of sputum and fever. Acute exacerbation of chronic bronchitis (AECB) is typically caused by an infection, such as a bacterial or viral infection. In cases of AECB, the infection can lead to airway inflammation and blockage, resulting in the common symptoms of COPD like coughing, wheezing, and shortness of breath. Other potential causes of AECB include exposure to irritants and allergens—such as cigarette smoke, ozone, or dust—and pre-existing medical conditions like asthma or a weakened immune system. Of course, any underlying cause should be identified and treated for a successful outcome (Crisafulli et al., 2020).

 

What is a likely pathogen associated with an acute exacerbation of chronic bronchitis in A.M.?

Streptococcus pneumonia (pneumococcus) is a common bacterium that can cause acute exacerbations of chronic bronchitis (AECB). Streptococcus pneumonia is a Gram-positive, aerobic, facultative pathogen that is found in the nasopharynx of healthy individuals. It is also the most common cause of community-acquired pneumonia, which can lead to an acute exacerbation of chronic bronchitis.

The pathogenesis of Streptococcus pneumonia is multifactorial and includes the following factors: adherence to epithelial cells, production of proteases and toxins, and evasion of the innate immune response. These virulence factors allow Streptococcus pneumonia to colonize the respiratory tract and cause disease. Pneumococcal infections can lead to inflammation and narrowing of the airways, which can cause increased coughing and shortness of breath. In some cases, pneumococcal infections can also spread to other parts of the body, such as the lungs, bloodstream, or middle ear, and cause severe infections such as pneumonia, bacteremia, or meningitis. Antibiotic therapy is usually required to treat pneumococcal infections, as it helps to reduce the bacterial load, relieve symptoms, and prevent further exacerbations. Therefore, if a patient with AECB is found to have a pneumococcal infection, they would likely require antibiotic therapy to treat their condition (Jacobs et al., 2019).

2. What antibiotic would be most appropriate to treat an acute exacerbation of chronic bronchitis in A.M.?

If an acute exacerbation of chronic bronchitis (AECB) is caused by Streptococcus pneumonia, the antibiotic appropriate for its treatment is Amoxicillin-clavulanate: This is a combination of two antibiotics that is effective against a wide range of bacteria, including gram-negative bacteria such as Pseudomonas aeruginosa. There are several reasons why amoxicillin-clavulanate would be the best antibiotic to use for treating an acute exacerbation of chronic bronchitis.

First, this antibiotic has a broad spectrum of activity that allows it to effectively treat a variety of pathogens, including Streptococcus pneumonia. Additionally, amoxicillin-clavulanate is available in both oral and intravenous formulations, making it easy to use in a variety of settings. Most importantly, amoxicillin-clavulanate is known to be highly effective at treating Streptococcus pneumoniae infections. In fact, it has been shown to be up to 98% effective at eradicating this pathogen. For these reasons, amoxicillin-clavulanate is the antibiotic of choice for treating acute exacerbations of chronic bronchitis.

It is generally prescribed in an oral dosage form, taken twice a day at 8-hour intervals. The dosage recommended for adults is 500 mg to 1000 mg every 12 hours, depending on the severity of the infection. It is important to take the medication regularly and complete the full course of treatment even if symptoms improve after a few days. This helps ensure that the infection is fully treated and prevents any recurrence or further complications.

What is the mechanism of action of the medication of choice in question #3? Provide rationale.

Amoxicillin-clavulanate is a combination antibiotic that is used to treat a variety of bacterial infections, including acute exacerbations of chronic bronchitis (AECB) caused by Pseudomonas aeruginosa. Amoxicillin is a penicillin-type antibiotic that works by inhibiting the synthesis of the bacterial cell wall. However, many strains of bacteria, including Pseudomonas aeruginosa, have developed resistance to amoxicillin through the production of beta-lactamases, enzymes that can break down the amoxicillin molecule (Lexicomp, 2017).

Clavulanate, also known as clavulanic acid, is a beta-lactamase inhibitor. When combined with amoxicillin, clavulanate acts to inhibit the action of beta-lactamases produced by the bacteria, thereby preventing the breakdown of the amoxicillin and increasing its effectiveness against resistant strains of bacteria. Therefore, the mechanism of action of amoxicillin-clavulanate in treating AECB caused by Pseudomonas aeruginosa is to inhibit the synthesis of the bacterial cell wall, with clavulanate providing enhanced activity against beta-lactamase-producing bacteria such as Pseudomonas aeruginosa. This allows amoxicillin to effectively target the bacteria and reduce the infection.

It is important to note that the efficacy of amoxicillin-clavulanate against Pseudomonas aeruginosa may still be limited, and treatment with antibiotics that are active against this organism, such as carbapenems or fluoroquinolones, may be more appropriate. Additionally, the use of combination antibiotic therapy may be considered for severe or complicated infections (Li et al., 2019).

3. What kind of counseling points would you provide for A.M.?

When counseling Anthony Miller who is suffering from acute exacerbation of chronic bronchitis (AECB), several important points should be emphasized to improve overall health and prevent future exacerbations. Medication Compliance: Ensure that Anthony Miller understands the importance of taking his antibiotics as prescribed, even if they start feeling better before the medication is finished. Emphasize that skipping doses or stopping the medication prematurely can allow the bacteria to continue to grow and increase the risk of antibiotic resistance.

Lifestyle Changes: Encourage Anthony Miller to quit any form of smoking and avoid exposure to environmental irritants such as second-hand smoke and air pollution. Provide information on healthy lifestyle habits, such as regular exercise and a balanced diet, to improve lung function and overall health.

Respiratory Hygiene: Advise Anthony Miller to cover their mouth and nose with a tissue when coughing or sneezing, and to wash their hands frequently to prevent the spread of respiratory infections.

Vaccination: Recommend that the patient receive the pneumococcal vaccine to reduce their risk of developing severe pneumococcal infections. Additionally, the flu vaccine may also be recommended to reduce the risk of respiratory infections during the flu season.

Follow-Up Care: Schedule follow-up appointments with the patient’s healthcare provider to monitor their progress and make any necessary adjustments to their treatment plan. Encourage the patient to seek medical attention promptly if their symptoms worsen or if they develop any new symptoms. These counseling points can help improve the patient’s health and prevent future exacerbations of their chronic bronchitis, as well as reduce the risk of complications and improve their overall quality of life.

References

Crisafulli, E., Manco, A., & Torres, A. (2020). How may we improve clinical outcomes for patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease? A narrative review about possible therapeutic and preventive strategies. Expert Review of Respiratory Medicine, 14(5), 493–500. https://doi.org/10.1080/17476348.2020.1732823

Jacobs, D. M., Pandit, U., & Sethi, S. (2019). Acute exacerbations in chronic obstructive pulmonary disease. Current Opinion in Infectious Diseases, 32(2), 143–151. https://doi.org/10.1097/qco.0000000000000533

Lexicomp. (2017). Drug Information Handbook for Advanced Practice Nursing (17 ed.). Wolters Kluwer Clinical Drug Information.

Li, Z., Yuan, X., Yu, L., Wang, B., Gao, F., & Ma, J. (2019). Procalcitonin-guided antibiotic therapy in acute exacerbation of chronic obstructive pulmonary disease. Medicine, 98(32), e16775. https://doi.org/10.1097/md.0000000000016775

Taketamo, C. K. (2017). Pediatric and Neonatal Dosage Handbook (24th ed.). Lexicomp Incorporated.

Woo, T. M., & Robinson, M. V. (2020). Pharmacotherapeutics for Advanced practice Nurse prescribers for Advanced practice Nurse prescribers (5Tth ed.). F.A. Davis Company. Retrieved Feb 6, 2023

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

NU 641 Week 6. Case Study